News
The CATALIS Network Rolls Out a New Strategic Plan for 2024-2028
The CATALIS Network Rolls Out a New Strategic Plan for 2024-2028 The CATALIS Quebec Network is pleased to announce the rollout of its new 2024-2028 Strategic Plan in collaboration with its partners, the Ministry of Health and Social Services (MHSS) and the Ministry of Economy, Innovation and Energy (MEIE). An Innovative and Ambitious Strategic Plan for 2024-2028
The CATALIS Network Supports Provincial Efforts for an Even More Innovative and Productive Clinical Research Environment
The CATALIS Network Supports Provincial Efforts for an Even More Innovative and Productive Clinical Research Environment Since its inception, CATALIS Quebec’s government mandate has been to act as a neutral and agile entity for mobilizing and coordinating efforts aimed at optimizing Quebec’s clinical research environment. CATALIS has facilitated more than 280 advisory committees and working groups with members of
3 Pharmaceutical Companies Join the CATALIS Network
3 Pharmaceutical Companies Join the CATALIS Network CATALIS is pleased to welcome the pharmaceutical companies Alexion, Lilly Canada and Novo Nordisk Canada Inc. to its Network of partners. These companies join the many industry partners committed to the Network, namely Abbvie, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences Canada, GSK, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda,
2 Patient Organizations Join the CATALIS Network
2 Patient Organizations Join the CATALIS Network New organizations join the CATALIS Network: Asthma Canada and Kidney Cancer Canada. They join more than 30 patient organizations and patient partners who represent the patient’s voice within the Network and contribute to CATALIS’ mission of optimizing clinical research in Quebec, in order to accelerate the development of innovative patient care for
The Chaudière-Appalaches Integrated Health and Social Services Centre Authorized a First Clinical Trial in 8.4 Weeks With the FAST TRACK Evaluation Service and Recruited the First Canadian Participant
The Chaudière-Appalaches Integrated Health and Social Services Centre Authorized a First Clinical Trial in 8.4 Weeks With the FAST TRACK Evaluation Service and Recruited the First Canadian Participant The very first collaboration between the Chaudière-Appalaches Centre intégré de santé et de services sociaux (integrated health and social services centre or CISSS) and CATALIS’ FAST TRACK Evaluation Service has been
Bayer: The CHUM Was Ranked First in the World After Using the FAST TRACK Evaluation Service for the First Time
Bayer: The CHUM Was Ranked First in the World After Using the FAST TRACK Evaluation Service for the First Time The Bayer pharmaceutical company used the FAST TRACK Evaluation Service for the first time to accelerate the authorization of its PAnTHA advanced prostate cancer trial at the Centre hospitalier de l’Université de Montréal (CHUM) in 10.4 weeks, with site
A New Brand Identity for the FAST TRACK Evaluation Service
Almost 2 years after its inauguration, the FAST TRACK Evaluation Service is unveiling a new brand identity. Officially launched by the CATALIS Network in September 2022, the FAST TRACK Evaluation Service aims to authorize clinical trials in ≤ 8 weeks. We are pleased to announce that, to date, the service has enabled the authorization of 37 clinical trials conducted by
Pharmaceutical Company Gilead Sciences Canada Joins the CATALIS Network
Pharmaceutical Company Gilead Sciences Canada Joins the CATALIS Network CATALIS is pleased to welcome the pharmaceutical company Gilead Sciences Canada Inc. to its Network of partners. Gilead joins numerous industry partners that are actively involved in the Network: Abbvie, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vertex. These partners support
4 New Patient Organizations Join the CATALIS Network
4 New Patient Organizations Join the CATALIS Network The CATALIS Network keeps growing. Bladder Cancer Canada, and the Canadian Liver Foundation, and Fighting Blindness Canada have joined 3 patient partners and more than 30 patient organizations. Together, they represent the patient’s voice and contribute to CATALIS’ mission, which is to optimize clinical research in Quebec, in order to
The CATALIS Network Draws on the Expertise of 3 Patient Partners
The CATALIS Network Draws on the Expertise of 3 Patient Partners The CATALIS Network is delighted to rely on the support of patient partners Casandra Poitras, Raymond Vles and Catherine Wilhelmy. Catherine Wilhelmy has been a member of the Patient Advisory Committee since its inception, while Casandra Poitras and Raymond Vles are already involved in the Patient Advisory Committee